Stoke Therapeutics (NASDAQ:STOK) Trading Up 0.1%

Stoke Therapeutics (NASDAQ:STOK)’s stock price was up 0.1% during trading on Monday . The stock traded as high as $30.02 and last traded at $29.90, approximately 4,529 shares changed hands during mid-day trading. A decline of 97% from the average daily volume of 174,585 shares. The stock had previously closed at $29.87.

Several research analysts recently commented on STOK shares. Zacks Investment Research upgraded Stoke Therapeutics from a “hold” rating to a “buy” rating and set a $23.00 price target on the stock in a research note on Wednesday, October 16th. HC Wainwright started coverage on Stoke Therapeutics in a report on Friday, October 25th. They issued a “buy” rating and a $30.00 price objective for the company. Cowen reissued a “buy” rating on shares of Stoke Therapeutics in a report on Thursday, August 15th. Credit Suisse Group started coverage on Stoke Therapeutics in a report on Monday, July 15th. They issued an “outperform” rating and a $35.00 price objective for the company. Finally, Canaccord Genuity started coverage on Stoke Therapeutics in a report on Monday, July 15th. They issued a “buy” rating and a $44.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and an average price target of $33.20.

The stock’s fifty day moving average price is $24.01.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($1.54) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.96) by ($0.58). As a group, research analysts anticipate that Stoke Therapeutics will post -2.12 EPS for the current fiscal year.

In other news, major shareholder Rtw Investments, Lp acquired 31,560 shares of the stock in a transaction that occurred on Tuesday, October 1st. The stock was purchased at an average cost of $21.96 per share, with a total value of $693,057.60. Over the last three months, insiders purchased 205,216 shares of company stock valued at $5,771,421.

Large investors have recently bought and sold shares of the company. Platinum Investment Management Ltd. bought a new position in shares of Stoke Therapeutics during the second quarter valued at approximately $29,000. Strs Ohio bought a new position in shares of Stoke Therapeutics during the third quarter valued at approximately $51,000. Victory Capital Management Inc. bought a new position in shares of Stoke Therapeutics during the second quarter valued at approximately $73,000. Ladenburg Thalmann Financial Services Inc. bought a new position in shares of Stoke Therapeutics during the second quarter valued at approximately $88,000. Finally, Morgan Stanley bought a new position in shares of Stoke Therapeutics during the second quarter valued at approximately $104,000. 43.44% of the stock is owned by institutional investors.

About Stoke Therapeutics (NASDAQ:STOK)

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc has a partnership with Invitae Corporation to offer epilepsy panel testing.

Featured Article: How much can an individual set aside as a catch-up contribution?

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.